Compare CSTL & GILT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSTL | GILT |
|---|---|---|
| Founded | 2007 | 1987 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Radio And Television Broadcasting And Communications Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 722.8M | 599.3M |
| IPO Year | 2019 | 1997 |
| Metric | CSTL | GILT |
|---|---|---|
| Price | $35.08 | $7.36 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 3 |
| Target Price | ★ $46.70 | $19.20 |
| AVG Volume (30 Days) | 323.1K | ★ 988.8K |
| Earning Date | 11-05-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $344,229,000.00 | N/A |
| Revenue This Year | $8.68 | $12.44 |
| Revenue Next Year | $12.08 | $11.62 |
| P/E Ratio | ★ N/A | $42.82 |
| Revenue Growth | ★ 3.66 | N/A |
| 52 Week Low | $17.72 | $7.23 |
| 52 Week High | $44.28 | $20.99 |
| Indicator | CSTL | GILT |
|---|---|---|
| Relative Strength Index (RSI) | 52.00 | 29.24 |
| Support Level | $33.90 | $7.23 |
| Resistance Level | $37.42 | $10.39 |
| Average True Range (ATR) | 1.76 | 0.31 |
| MACD | 0.23 | 0.02 |
| Stochastic Oscillator | 47.06 | 6.71 |
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.
Gilat Satellite Networks Ltd is a provider of satellite-based broadband communications. The company designs and manufactures ground-based satellite communications equipment and provides comprehensive solutions and end-to-end services. Its portfolio includes a cloud-based satellite network platform, very small aperture terminals (VSATs), amplifiers, high-speed modems, on-the-move antennas and high-power solid-state power amplifiers (SSPAs), block-up converters (BUCs), and Transceivers. The company operates in three operating segments: Gilat Commercial Division, Gilat Defense Division, and Gilat Peru Division. The majority of its revenue is generated from the Gilat Commercial segment.